Skip to Content
Søg Menu

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

In this MEDtalk, Dr. Petros Grivas presents the long-term outcomes from the JAVELIN Bladder 100 trial, discussing the impact of avelumab as first-line maintenance therapy for advanced urothelial carcinoma in patients with and without diabetes.
Petros Grivas

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatacancer Play the Video 18:34

Highlights From the Nordic Urothelial Cancer Oncology Group (NUCOG)

/ Katrine Ørum / Helle Pappot / Anders Ullén
Blærecancer

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Nyrecancer
Dag Stormoen

Immunterapi og antibody-drug conjugates vil få en central plads i fremtidens behandling af blærecancer

/ Dag Rune Stormoen
ASCOGU25Blærecancer Play the Video 04:20
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blærecancer Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatacancer

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blærecancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Nyrecancer
Philippe Barthélémy

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

/ Philippe Barthélémy
ASCOGU25 Play the Video 03:28
Back to top